Theralase Expands Intellectual Property Portfolio
09 December 2021 - 11:00PM
Theralase® Technologies Inc. (“
Theralase®” or the
“
Company”) (
TSXV: TLT)
(
OTCQB: TLTFF), a clinical stage pharmaceutical
company focused on the research and development of light activated
Photo Dynamic Compounds (“
PDCs”) and their
associated drug formulations, used to destroy various cancers,
bacteria and viruses, safely and effectively, is pleased to
announce that the Company has expanded its Intellectual Property
(“
IP”) portfolio.
Theralase® has recently been granted an Indian
patent for “Metal-Based Coordination Complexes as Photodynamic
Compounds and their Use.”
This patent encompasses numerous
Theralase® PDCs destined for the Indian market; most
importantly, TLD-1433, which is currently under clinical
investigation in a Phase II Non-Muscle Invasive Bladder Cancer
(“NMIBC”) clinical study, being conducted in
Canada and the United States.
The Mechanism of Action (“MOA”)
of the patented Theralase® PDCs involves localization of the PDC
inside the cancer cells of interest and then activating it by laser
light to produce radical singlet oxygen and Reactive Oxygen Species
(“ROS”), temporally and spatially to destroy the
cancer cells, with minimum impact on healthy cells.
This patent further strengthens the extensive
portfolio of patents already held by Theralase®, by differentiating
TLD-1433 cancer therapy versus its competitors and providing
Theralase® a sustainable first-mover competitive advantage in
PDC technology in the oncology market. Theralase® is focused on
increasing shareholder value, by providing the Company
international patents to protect its unique technology, as the
Company moves closer towards commercialization.
Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief
Executive Officer (“CEO”) and Chief Scientific
Officer (“CSO”), Theralase®, stated that, “This
patent is strategic to opening up new international opportunities
for Theralase® by expanding its IP portfolio of medical laser and
oncology focused technologies internationally. Theralase®’s
long-term strategy is to commercialize the Anti-Cancer Therapy
(“ACT”) division technology commencing with NMIBC
and expanding into Glio Blastoma Multiforme
(“GBM”), Non-Small Cell Lung Cancer
(“NSCLC”) and other various cancer indications to
provide a safe, effective and rapid alternative treatment option
for patients inflicted with these deadly diseases. The ability to
provide personalized treatment for cancer patients to 'hunt and
destroy' their cancer and prevent its recurrence and progression,
all in a single or dual treatment, remains at the forefront of our
research and development objectives.”
About Theralase® Technologies
Inc.Theralase® is a clinical stage pharmaceutical company
dedicated to the research and development of light activated Photo
Dynamic Compounds and their associated drug formulations intended
to, safely and effectively, destroy various cancers, bacteria and
viruses.
Additional information is available at
www.theralase.com and www.sedar.com
Forward Looking Statement:
This news release contains "forward-looking
statements" which reflect the current expectations of the Company's
management for future growth, results of operations, performance,
business prospects and opportunities. Such statements include, but
are not limited to, statements regarding the Company's proposed
development plans with respect to Photo Dynamic Compounds and their
drug formulations. Wherever possible, words such as
"may", "would",
"could", "should",
"will", "anticipate",
"believe", "plan",
"expect", "intend",
"estimate", "potential for" and
similar expressions have been used to identify these
forward-looking statements. These statements reflect management's
beliefs with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions;
including, with respect to the ability of the Company to:
adequately fund, secure the requisite regulatory approvals to
commence and successfully complete a Phase II NMIBC clinical study
in a timely fashion and implement its commercialization plans. Many
factors could cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements; including, without limitation,
those listed in the filings made by the Company with the Canadian
securities regulatory authorities (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the press release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements. The Company
disclaims any intention or obligation to revise forward-looking
statements whether as a result of new information, future
developments or otherwise except as required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For More Information:
1.866.THE.LASE (843.5273)416.699.LASE
(5273)www.theralase.com
Kristina HacheyChief Financial
Officerkhachey@theralase.com416.699.LASE (5273) x 224
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Aug 2023 to Aug 2024